Pharmaceuticals

Global Next Generation Drug Conjugates Market 2025–2029: Competitive Insights and Opportunities

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Next Generation Drug Conjugates Industry In 2025?

The market size for next generation drug conjugates has experienced rapid expansion over recent years. Projections indicate it will increase from $2.15 billion in 2024 to $2.47 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion has been driven by factors such as enhanced comprehension of tumor biology, the proven efficacy of initial drug conjugates, a rise in oncology cases, greater investment and funding, and heightened patient advocacy and awareness.

The next generation drug conjugates market is projected to experience swift expansion in the coming years. This market is anticipated to reach $4.41 billion by 2029, achieving a compound annual growth rate (CAGR) of 15.6%. This projected growth is driven by factors such as an increase in combination therapies, broadening clinical research, a concentrated effort on rare diseases, various strategic collaborations, and the emergence of new bioinformatics tools. Key developments foreseen during this period encompass progress in monoclonal antibody technology, the application of combination therapies featuring JAK inhibitors, the integration of artificial intelligence into drug development, the continued evolution of biosimilars, and improvements in subcutaneous formulations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp

What Are The Key Drivers Of Growth In The Next Generation Drug Conjugates Market?

The escalating occurrence of cancer is projected to stimulate the expansion of the next-generation drug conjugates market in the future. Cancer describes a collection of illnesses marked by the unchecked proliferation and dissemination of aberrant cells throughout the body. The increase in cancer incidence primarily stems from an aging demographic, lifestyle choices, environmental exposures, enhanced detection methods, genetic predispositions, and infectious agents. Next-generation drug conjugates assist in combating cancer by delivering targeted therapies directly to malignant cells, thereby boosting treatment effectiveness while minimizing harm to healthy tissues. For instance, in August 2024, a report released by the Australian Institute of Health and Welfare, an Australia-based national agency for information and statistics on Australia’s health and welfare, projected that by 2034, Australia is anticipated to have approximately 209,000 new cancer diagnoses, a notable increase from the estimated 169,000 cases expected in 2024, reflecting the influence of a growing population and escalating cancer rates. Consequently, the rising prevalence of cancer is fueling the growth of the next-generation drug conjugates market.

What Are The Different Segment Classifications Within The Next Generation Drug Conjugates Market?

The next generation drug conjugates market covered in this report is segmented –

1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate

2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles

3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule

4) By Therapy: Monotherapy, Combination Therapy

5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications

Subsegments:

1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides

2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates

3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates

4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates

What Key Innovation Trends Are Fueling Advancements In The Next Generation Drug Conjugates Market?

Leading firms within the next-generation drug conjugates market are utilizing strategic partnerships to improve R&D capacities, quicken product development, and grow their footprint in the market. These alliances involve companies combining their respective strengths and resources to achieve shared advantages and favorable outcomes. As an illustration, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, collaborated with AbCellera Biologics Inc., a Canada-based biotechnology company, with the aim of creating pioneering precision antibody-drug conjugates (ADCs) for oncology. This collaboration will focus on the identification, evolution, and market introduction of novel antibody-drug conjugates (ADCs), commencing with an initiative centered on a SMARCA degrader connected to a new antibody. The intent of this approach is to extend the therapeutic uses of Prelude’s small-molecule SMARCA2 selective degraders to a broader patient base, particularly for individuals with cancers not linked to SMARCA4 mutations.

Which Major Industry Participants Are Leading The Next Generation Drug Conjugates Market Growth?

Major companies operating in the next generation drug conjugates marker are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/next-generation-drug-conjugates-global-market-report

Which Region Is Projected To Lead The Next Generation Drug Conjugates Market During The Forecast Period?

North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Next Generation Drug Conjugates Market Report:

https://www.thebusinessresearchcompany.com/customise?id=19124&type=smp

Browse Through More Reports Similar to the Global Next Generation Drug Conjugates Market 2025, By The Business Research Company

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Conjugated Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodie-global-market-report

Conjugate Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795